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In [Table 4](#t1-copd-7-765){ref-type="table"}, the value at column 5, row 15 should have been 4 instead of 2. The corrected table is below.

###### 

Summary of treatment-emergent adverse events

                                                      Number of subjects (%)                                        
  --------------------------------------------------- ------------------------ ----------- ------------ ----------- -----------
  Treatment period (weeks 1--26)                                                                                    
   Any AE                                             62 (30.0)                57 (26.3)   62 (29.5)    70 (33.5)   67 (31.6)
   Severe or life-threatening AEs                     6 (2.9)                  9 (4.1)     15 (7.1)     16 (7.7)    12 (5.7)
   Life-threatening AEs                               0                        4 (1.8)     4 (1.9)      4 (1.9)     3 (1.4)
   Serious AEs                                        8 (3.9)                  16 (7.4)    15 (7.1)     17 (8.1)    12 (5.7)
   Discontinuations due to AEs                        2 (1.0)                  10 (4.6)    9 (4.3)      6 (2.9)     8 (3.8)
   Deaths                                             1 (0.4)                  1 (0.4)     3 (1.4)      3 (1.4)     1 (0.4)
   Pneumonia                                          1 (0.5)                  2 (0.9)     0            2 (1.0)     1 (0.5)
   Treatment-related AEs                              9 (4.3)                  13 (6.0)    12 (5.7)     15 (7.2)    10 (4.7)
  Treatment period + safety extension (weeks 1--52)                                                                 
   Any AE                                             78 (37.7)                78 (35.9)   86 (41.07)   88 (42.1)   
   Severe or life-threatening AEs                     7 (3.4)                  21 (9.7)    19 (9.0)     24 (11.5)   
   Life-threatening AEs                               1 (0.5)                  6 (2.8)     4 (1.9)      6 (2.9)     
   Serious AEs                                        13 (6.3)                 29 (13.4)   22 (10.5)    29 (13.9)   
   Discontinuations due to AEs                        4 (1.9)                  14 (6.5)    13 (6.2)     11 (5.3)    
   Deaths                                             1 (0.4)                  3 (1.3)     3 (1.4)      8 (3.8)     
   Pneumonia                                          1 (0.5)                  4 (1.8)     2 (1.0)      4 (1.9)     
   Treatment-related AEs                              12 (5.8)                 18 (8.3)    15 (7.1)     17 (8.1)    

**Abbreviations:** AE, adverse event; bid, twice daily; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination.
